Evaluating the Prevail Drug-Coated Balloon for Treating In-stent Restenosis and Small Vessel Disease in Coronary Artery Disease
Led by Medtronic Vascular · Updated on 2026-10-21
1205
Participants Needed
79
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the Prevail Drug-Coated Balloon DCB in people with coronary artery disease undergoing percutaneous coronary intervention PCI. The study includes two groups one with in-stent restenosis ISR randomized to receive either the Prevail DCB or the Agent DCB, and another with de novo lesions in small vessel disease DNSV treated with the Prevail DCB and compared to historical data from drug-eluting stents. The study aims to assess the clinical safety and effectiveness of the Prevail DCB in these conditions.
Participants in the ISR group will be randomly assigned to receive either the Prevail DCB or the Agent DCB during PCI to treat lesions in coronary arteries previously treated with drug-eluting or bare metal stents. The DNSV group will receive the Prevail DCB for new lesions in small vessels. Both devices are paclitaxel-coated balloons designed for vessels 2.00 mm to 4.00 mm in diameter. Enrollment will take place at about 85 global sites over approximately 12 months.
Participants will be followed with clinical assessments for up to 5 years or until study exit or death. Researchers will monitor outcomes such as restenosis, cardiac events including myocardial infarction and death, and the need for repeat procedures at various timepoints from hospital discharge through 5 years. Safety and efficacy will be tracked through visits and evaluations at 30 days, 6, 12, 24, 36, 48, and 60 months after the procedure to gather long-term data on the devices.
CONDITIONS
Brief Title
Prevail Global Study
Research Team
J
Jeroen Frijhoff
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Prevail drug‑coated balloon
Agent drug‑coated balloon
Drug‑eluting stent (DES)
What this option is
A paclitaxel‑coated balloon catheter (Prevail DCB) being evaluated for use in ISR and de novo small vessel coronary lesions
A similar paclitaxel‑coated balloon catheter (Agent DCB) being investigated for treatment of ISR
A drug‑eluting stent that is routinely used in clinical practice for ISR and small vessel disease
Role in trial
Investigational arm A
Investigational arm B
Not part of the trial—provided for context only
Primary use or purpose
To treat in‑stent restenosis and de novo small vessel lesions via drug‑coated balloon angioplasty
To treat in‑stent restenosis using drug‑coated balloon angioplasty
Restore vessel patency by scaffolding and antiproliferative drug delivery in ISR or small vessel disease
How it is given or used
Delivered via percutaneous transluminal coronary angioplasty with a paclitaxel‑coated balloon sized 2.00–4.00 mm
Delivered via PTCA with a paclitaxel‑coated balloon catheter sized 2.00–4.00 mm
Implanted via PCI to leave a drug‑eluting metal scaffold in the vessel
Evidence status
No published results yet; trial ongoing to assess safety and 1‑year outcomes
No published results yet; efficacy under evaluation in trial
Well established efficacy in ISR and de novo small vessel PCI
Important limitations
Efficacy and safety compared only to another DCB; no long‑term data yet
Same as above—no comparative long‑term evidence outside trial
Implanted metal risk long‑term issues and need for prolonged antiplatelet therapy
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Negative pregnancy test
Diagnosis of stable or unstable angina, positive functional test, or stable NSTEMI
Life expectancy greater than 1 year
Willingness and ability to follow study procedures and attend required follow-up visits
You will not qualify if you...
Allergy or contraindication to antiplatelet medications or untreatable sensitivity to contrast media
Known allergy or significant sensitivity to paclitaxel or related compounds
Platelet count below 100,000 or above 700,000 cells/mm³, or white blood cell count below 3,000 cells/mm³
Renal insufficiency or failure
Recent acute myocardial infarction
Previous PCI on target vessel within 6 months before the procedure
Planned PCI of any vessel within 72 hours after procedure or on target vessel within 12 months after procedure
History of stroke or transient ischemic attack
Active peptic ulcer or upper gastrointestinal bleeding
History of bleeding disorders or refusal of blood transfusions
Left ventricular ejection fraction below 30%
Planned surgery that interrupts recommended duration of dual antiplatelet therapy
Participation in another investigational drug or device study that conflicts with this trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 year
Participants undergo percutaneous coronary intervention using either the Prevail Drug-Coated Balloon or the Agent Drug-Coated Balloon to treat coronary artery lesions.
Visits at hospital discharge, 30 days, and 6, 12 months, then annually up to 5 years
Follow-up
Duration - Up to 5 years
Participants are monitored with clinical assessments to track device safety and effectiveness, including heart-related events and possible repeat procedures.
Follow-up visits at 24, 36, 48, and 60 months after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Study of Yiyang Huoluo Decoction Combined with Western Medicine to Treat Coronary Heart Disease and Atherosclerosis in Older Adults
Evaluating Pre-Procedural Intracoronary Nicorandil to Prevent Reduced TIMI Flow in Patients Undergoing Percutaneous Coronary Intervention for Coronary Artery Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.